REG - Ondine Biomedical - Notice of AGM

Ondine BiomedicalAnnouncement

Today 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260604:nRSD9124Ga&default-theme=true

RNS Number : 9124G  Ondine Biomedical Inc.  04 June 2026

4 June 2026

 

ONDINE BIOMEDICAL INC.

("Ondine Biomedical", "Ondine" or the "Company")

 

Notice of AGM

 

Ondine Biomedical Inc. (AIM: OBI) announces that the notice of the Company's
2026 Annual General Meeting ("AGM") and the associated form of proxy have been
published today on the Company's website
at https://ondinebio.com/investors/reports-documentation/
(https://ondinebio.com/investors/reports-documentation/) .

 

Printed copies of the notice of AGM and form of proxy will be posted today to
registered shareholders who have elected to receive paper communications.

 

The Company's AGM will be held virtually at 16:00 BST (08:00 Pacific time) on
30 June 2026. Details of how to access the meeting are contained in the notice
of AGM.

 

All shareholders are encouraged to submit their vote by proxy, well in advance
of the meeting. Details of how to vote by proxy are contained in the notice of
AGM. All valid proxy votes (whether submitted electronically or in hard copy
form) will be included in the poll vote to be taken at the meeting.

 

The items of business to be voted on at the Meeting are:

·    the re-election of Carolyn Cross, Nicolas G. Loebel, Jean Charest,
Jean Duvall, Junaid Bajwa, and Margaret Shaw as directors of the Company to
hold office until the 2027 annual meeting of shareholders or until their
successors are elected and qualified, subject to earlier resignation or
removal.

·    the re-appointment of PricewaterhouseCoopers LLP, Chartered
Professional Accountants, as auditors for the Company for the ensuing year;
and

·    to transact such other business as may properly come before the
Meeting.

 

The result of the AGM will be announced after its conclusion and published on
the Company's website.

 

 

**ENDS**

 Ondine Biomedical Inc.
 Angelika Vance, Corporate Communications                         +001 (604) 838 2702

 Strand Hanson Limited (Nominated & Joint Financial Adviser)
 James Harris, Richard Johnson                                    +44 (0)20 7409 3494

 Peel Hunt LLP (Broker & Joint Financial Adviser)
 James Steel, Dr. Chris Golden                                    +44 (0)20 7418 8900

 5654 & Company (Financial PR and IR Adviser)                     ondinebiomedical@5654.co.uk
 Matthew Neal, Chris Gardner, Melissa Gardiner                    +44 0791 7800 011
                                                                  +44 0775 7697 357

 

 

About Ondine Biomedical Inc.

 

Ondine Biomedical Inc. is a Canadian life sciences company and leader in
light-activated antimicrobial therapies ('photodisinfection') for the
prevention and treatment of infections, including those caused by
multidrug-resistant organisms. Ondine has a pipeline of investigational
products, based on its proprietary photodisinfection technology, in various
stages of development.

 

Ondine's nasal photodisinfection system is CE-marked in Europe and is approved
for nasal decolonisation in Canada, Australia, Mexico, and several other
countries under the name Steriwave(®). In the US, it has been granted
Qualified Infectious Disease Product designation and Fast Track status by the
FDA and is currently undergoing clinical trials for regulatory approval.
Products beyond nasal photodisinfection include therapies for a variety of
medical indications such as chronic sinusitis, ventilator-associated
pneumonia, burns, and other indications.

U.S. Regulatory Status Disclaimer

Steriwave(®) is CE-marked in Europe and is approved for nasal decolonisation
in Canada, the United Kingdom, Australia, and Mexico. In the United States,
Steriwave has been granted Qualified Infectious Disease Product (QIDP)
designation and Fast Track status by the U.S. Food and Drug Administration
(FDA). It is currently undergoing clinical trials in the United States to
support regulatory approval and is limited by United States law to
investigational use only. It is not commercially available for sale or
clinical use in the United States.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NOAUORWRNSUNRAR



            Copyright 2019 Regulatory News Service, all rights reserved